WST (West Pharmaceutical Services) Interest Expense : $-2 Mil (TTM As of Mar. 2025)

View and export this data going back to 1973. Start your Free Trial

What is West Pharmaceutical Services Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. West Pharmaceutical Services's interest expense for the three months ended in Mar. 2025 was $ -0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $-2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. West Pharmaceutical Services's Operating Income for the three months ended in Mar. 2025 was $ 107 Mil. West Pharmaceutical Services's Interest Expense for the three months ended in Mar. 2025 was $ -0 Mil. West Pharmaceutical Services's Interest Coverage for the quarter that ended in Mar. 2025 was 267.50. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

West Pharmaceutical Services Interest Expense Historical Data

The historical data trend for West Pharmaceutical Services's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Interest Expense Chart

West Pharmaceutical Services Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-8.20

-7.90

-9.00

-3.00

West Pharmaceutical Services Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-1.60	-1.50	-0.70	0.80	-0.40

West Pharmaceutical Services Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2 Mil.

West Pharmaceutical Services (NYSE:WST) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

West Pharmaceutical Services's Interest Expense for the three months ended in Mar. 2025 was $-0 Mil. Its Operating Income for the three months ended in Mar. 2025 was $107 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was $281 Mil.

West Pharmaceutical Services's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2025 )	/	Interest Expense (Q: Mar. 2025 )
	=	-1	*	107	/	-0.4
	=	267.50

The higher the ratio, the stronger the company's financial strength is.

West Pharmaceutical Services Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

WST:Mexico WPS:Germany WPS:Germany W2ST34:Brazil

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-1147

Website

https://www.westpharma.com

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Executives

Charles Witherspoon	officer: VP & Treasurer	530 HERMAN O WEST DRIVE, EXTON PA 19341
Eric Mark Green	officer: Chief Executive Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Silji Abraham	officer: Chief Digital & Trans Officer	5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Thomas W Hofmann	director	FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Chad Winters	officer: VP, CAO & Controller	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Annette F Favorite	officer: Sr. VP Human Resources Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark	officer: Senior Vice President	530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai	officer: VP Corp Development & Strategy	530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Bernard Birkett	officer: Sr VP, CFO & Treasurer	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Stephen H Lockhart	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph	director	9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay	officer: SVP, GC & Corporate Secretary	530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller	officer: Sr. VP, GC & Corp. Sec.	530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo	officer: SVP, Glob Ops and Supply Chain	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel	director	940 WINTER STREET, WALTHAM MA 02451